Trial Profile
A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib In Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary)
- Indications Brain cancer; Diffuse intrinsic pontine glioma; Glioma; Malignant melanoma; Neuroblastoma; Plexiform neurofibroma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms iMATRIX Cobi
- Sponsors Roche
- 17 Jun 2022 Results published in the Targeted Oncology
- 02 Apr 2022 This trial has been completed in France (Date of the global end of the trial : 21-Jul-2021), according to European Clinical Trials Database record.
- 04 Mar 2022 Status changed from active, no longer recruiting to completed.